SGLT-2 inhibitors were associated with a lower risk of death in individuals with and without CVD (HR: 0.56, 95% CI: 0.44–0.70; HR: 0.56, 95% CI: 0.50–0.63) as well as a reduction in heart failure hospitalizations (HR: 0.72, 95% CI: 0.63–0.82; HR: 0.61, 95% CI: 0.48–0.78). Here, SLC5A2 is linked to heart failure.